A Single Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Infected Subjects

Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BMS-790052 in Subjects Chronically Infected With Hepatitis C Virus Genotype 1

The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of daclatasvir in subjects with chronic hepatitis C infection

Key Inclusion Criteria:

• Chronically infected with hepatitis C virus genotype 1
• Treatment naive or treatment non-responders or treatment intolerant; and not co-infected with HIV or hepatitis B virus
• Hepatitis C virus RNA viral load of ≥ 10*5* IU/mL
• BMI 18 to 35 kg/m²

Key Exclusion Criteria:

• Any significant acute or chronic medical illness which is not stable or is not controlled with medication and not consistent with hepatitis C virus infection
• Major surgery within 4 weeks of study drug administration and any gastrointestinal surgery that could impact the absorption of study drug